According to the recent American [29] and European guidelines [30], all patients with MTC should undergo RET genetic screening to identify both hereditary cases erroneously diagnosed as sporadic and RET mutation carriers in MEN2 families. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.